Pitt Shield

Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment.

Authors: Ting CY, Fan CH, Liu HL, Huang CY, Hsieh HY, Yen TC, Wei KC, Yeh CK

Glioblastoma multiforme (GBM) is a highly malignant brain tumor. The blood-brain barrier (BBB) provides a major obstacle to chemotherapy since therapeutic doses cannot be achieved by traditional drug delivery without severe systemic cytotoxic effects. Recently, microbubble (MB)-enhanced focused ultrasound (FUS) was shown to temporally and locally disrupt the BBB thereby enhancing drug delivery into brain tumors. Here we propose the concept of smart, multifunctional MBs capable of facilitating FUS-induced BBB disruption while serving as drug-carrying vehicles and protecting drugs from rapid degradation. The designed MBs had a high loading capacity (efficiency of 68.01 ± 4.35%) for 1,3-bis(2-chloroethyl)-1- nitrosourea (BCNU). When combined with FUS (1-MHz), these BCNU-MBs facilitated local BBB disruption and simultaneously released BCNU at the target site, thus increasing local BCNU deposition. Encapsulation of BCNU in MBs prolonged its circulatory half-life by 5-fold, and accumulation of BCNU in the liver was reduced 5-fold due to the slow reticuloendothelial system uptake of BCNU-MBs. In tumor-bearing animals, BCNU-MBs with FUS controlled tumor progression (915.3%-39.6%) and improved median survival (29 days-32.5 days). This study provides a new approach for designing multifunctional MBs to facilitate FUS-mediated chemotherapy for brain tumor treatment.

Introduction

Purpose Drug delivery with BBB opening
Study Objective To evaluate concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles combined with focused ultrasound for treatment of brain glioma.
Animal model / Human subject Male Sprague-Dawley rats, 200-250 g
Disease model Glioma
MRI or image guidance method Ultrasound-guided
Targeted brain region(s) Striatum
Target coordinates AP: +0.5 mm, ML: +3 mm, DV: -4.5 mm
Cargo name and characteristics 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)
Route of administration Intravenous

Outcomes and Safety

Summary of Outcomes FUS combined with BCNU-loaded microbubbles successfully disrupted the BBB and triggered local release of the drug into the glioma. This concurrent delivery strategy significantly controlled tumor progression and improved median survival.
Duration of biological effect 32.5 days
Safety-related matter Encapsulation of BCNU in microbubbles with FUS-triggered local release reduced systemic toxicity, resulting in significantly lower AST and ALT levels (indicators of liver damage) compared to free BCNU administration.

Brain Region

Ultrasound Parameters

Ultrasound instrument Single-element FUS transducer (V302, Panametrics)
FUS Frequency 1 MHz
FUS Pressure 0.7 Mpa
FUS Mode pulsed
Pulse duration 10 ms
Duration of a single FUS session 2 min
Focal Characteristics Focal length: 60 mm; Aperture size: 38 mm; Focal depth: 26 mm
Treatment frequency Multiple sessions
Mechanical index 0.7

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search